| ²é¿´: 611 | »Ø¸´: 11 | ||||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | ||||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||||
000zgh000гæ (СÓÐÃûÆø)
|
[½»Á÷]
°ïæ¿´Ò»ÏÂÕ⼸¸ö¾ä×ÓÓÐûÓÐÎÊÌâ
|
|||
|
1. Like other malignant diseases, polygenes involvement coupled with accumulation of genetic and epigenetic changes make the high mortality rate without markedly changed. 2. HCC often coupled with liver dysfunction restrict the use of conventional chemotherapeutics as there are more or less non-selective toxicity with significant systemic side effects. Çë´óÏÀÃǰﰳ¿´¿´ÕâÁ½¸ö¾ä×ÓÓÐÎÊÌâÂð£¬Èç¹ûÓУ¬ÔõôÐ޸İ¡£¬¼±¼±¼±¡¡·Ç³£¸Ðл¹þ¡¡£¡£¡£¡ |
» ²ÂÄãϲ»¶
353Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
²ÄÁÏ»¯¹¤306·ÖÕÒºÏÊʵ÷¼Á
ÒѾÓÐ11È˻ظ´
µ÷¼Á
ÒѾÓÐ8È˻ظ´
¹¤¿ÆÇóµ÷¼Á
ÒѾÓÐ13È˻ظ´
¸´ÊÔµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤085600 310·ÖÇóµ÷¼Á
ÒѾÓÐ11È˻ظ´
Ò»Ö¾Ô¸±±¾©2£¬²ÄÁÏÓ뻯¹¤308Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
0817»¯Ñ§¹¤³ÌÓë¼¼ÊõÇóµ÷¼Á£¬Ò»Ö¾Ô¸Öк£Ñó319
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸µç×ӿƼ¼´óѧ085600²ÄÁÏÓ뻯¹¤ 329·ÖÇóµ÷¼Á
ÒѾÓÐ6È˻ظ´
chaokai
½ð³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 650.9
- É¢½ð: 35
- Ìû×Ó: 38
- ÔÚÏß: 9.9Сʱ
- ³æºÅ: 851208
- ×¢²á: 2009-09-18
- ÐÔ±ð: GG
- רҵ: ½ºÌåÓë½çÃæ»¯Ñ§
¡ï
linghanyuan(½ð±Ò+1,VIP+0):¹ÄÀøÐ³æ 9-25 15:28
linghanyuan(½ð±Ò+1,VIP+0):¹ÄÀøÐ³æ 9-25 15:28
| moralityÒѾ±íʾËÀÍöÂÊ ËùÒÔӦȥµôrate |
9Â¥2009-09-24 12:09:30
yuyang031985
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 1020.1
- É¢½ð: 22
- ºì»¨: 3
- Ìû×Ó: 372
- ÔÚÏß: 166.9Сʱ
- ³æºÅ: 328822
- ×¢²á: 2007-03-22
- ÐÔ±ð: GG
- רҵ: Ò©ÎïѧÆäËû¿ÆÑ§ÎÊÌâ
¡ï ¡ï
000zgh000(½ð±Ò+1,VIP+0): 9-14 09:03
linghanyuan(½ð±Ò+1,VIP+0):лл½»Á÷ 9-14 14:06
000zgh000(½ð±Ò+1,VIP+0): 9-14 09:03
linghanyuan(½ð±Ò+1,VIP+0):лл½»Á÷ 9-14 14:06
|
1. Like other malignant diseases, polygenes involvement coupled with the accumulation of genetic and epigenetic changes result in the high mortality rate, which was not changed significantly. 2. HCC often coupled with liver dysfunction restricts the use of conventional chemotherapeutics, for there is more or less non-selective toxicity of systemic side effects. ¿´¿´°É£¬×öÁ˲¿·Öµ÷Õû |

2Â¥2009-09-14 08:57:39
nono2009
³¬¼¶°æÖ÷ (ÎÄѧ̩¶·)
No gains, no pains.
-

ר¼Ò¾Ñé: +21105 - ·ÒëEPI: 3
- Ó¦Öú: 28684 (Ժʿ)
- ¹ó±ö: 513.911
- ½ð±Ò: 2555230
- É¢½ð: 27828
- ºì»¨: 2148
- ɳ·¢: 66666
- Ìû×Ó: 1602255
- ÔÚÏß: 65200.9Сʱ
- ³æºÅ: 827383
- ×¢²á: 2009-08-13
- ÐÔ±ð: GG
- רҵ: ¹¤³ÌÈÈÎïÀíÓëÄÜÔ´ÀûÓÃ
- ¹ÜϽ: ¿ÆÑмҳﱸίԱ»á
¡ï
linghanyuan(½ð±Ò+1,VIP+0):лл½»Á÷ 9-14 20:21
linghanyuan(½ð±Ò+1,VIP+0):лл½»Á÷ 9-14 20:21
|
Following the 2nd floor: 1. Like other malignant diseases, polygenes involvement coupled with the accumulation of genetic and epigenetic changes results in the high mortality rate, which was not changed significantly. (result in => results in?) |
4Â¥2009-09-14 20:01:18
goodtimega
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 4
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 8138.7
- É¢½ð: 570
- ºì»¨: 1
- Ìû×Ó: 1489
- ÔÚÏß: 527.5Сʱ
- ³æºÅ: 820248
- ×¢²á: 2009-08-02
- רҵ: ¸ß·Ö×Ó²ÄÁϽṹÓëÐÔÄÜ
¡ï
linghanyuan(½ð±Ò+1,VIP+0):лл½»Á÷ 9-14 20:22
linghanyuan(½ð±Ò+1,VIP+0):лл½»Á÷ 9-14 20:22
|
1. Similar to other malignant diseases, the involvement of polygenes coupled with the accumulation of genetic and epigenetic changes yields high mortality rate without significant change. 2. HCC coupled with liver dysfunction restricts the use of conventional chemotherapeutics, for there is more or less non-selective toxicity of systemic side effects. |
5Â¥2009-09-14 20:06:37














»Ø¸´´ËÂ¥